Compare GDEV & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDEV | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 364.8M |
| IPO Year | N/A | N/A |
| Metric | GDEV | DRUG |
|---|---|---|
| Price | $16.45 | $89.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $104.00 |
| AVG Volume (30 Days) | 2.0K | ★ 296.8K |
| Earning Date | 11-24-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.98 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $412,018,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $5.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.60 | $23.18 |
| 52 Week High | $42.20 | $123.75 |
| Indicator | GDEV | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 58.31 |
| Support Level | $14.60 | $85.65 |
| Resistance Level | $15.40 | $92.00 |
| Average True Range (ATR) | 0.37 | 9.24 |
| MACD | 0.15 | -0.08 |
| Stochastic Oscillator | 62.66 | 35.00 |
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.